Therapeutic Potential of Targeting the Cytochrome P450 Enzymes Using Lopinavir/Ritonavir in Colorectal Cancer: A Study in Monolayers, Spheroids and In Vivo Models
Maryam Alaei(Mashhad University of Medical Sciences), Amir Avan(Queensland University of Technology), Fatemeh Babaei(Mashhad University of Medical Sciences), Alireza Asadnia(Mashhad University of Medical Sciences), Seyedeh Elnaz Nazari(Mashhad University of Medical Sciences), Gordon A. Ferns(Brighton and Sussex Medical School), Elisa Giovannetti(University of Pisa), Hamid Tanzadehpanah(Mashhad University of Medical Sciences), Fereshteh Asgharzadeh(Mashhad University of Medical Sciences), Ibrahim Saeed Gataa(University of Kerbala), Mehrdad Moetamani‐Ahmadi(Mashhad University of Medical Sciences), Fatemeh Khojasteh‐Leylakoohi(Mashhad University of Medical Sciences), Hamid Fiuji(Mashhad University of Medical Sciences), Ghazaleh Pourali(Mashhad University of Medical Sciences), Seyed Mahdi Hassanian(Mashhad University of Medical Sciences), Majid Khazaei(Mashhad University of Medical Sciences), Mohammad Ali Kiani(Mashhad University of Medical Sciences), Alfred K. Lam(Griffith University)
Cited by 9
Related Papers
Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma
|International Journal of Oral Science|2020|259
Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer
|Drug Resistance Updates|2019|198
Entrectinib: a potent new TRK, ROS1, and ALK inhibitor
|Expert Opinion on Investigational Drugs|2015|153
Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer
|npj Precision Oncology|2023|146
Immunotherapy in NSCLC: A Promising and Revolutionary Weapon
|Advances in experimental medicine and biology|2017|143